Published in J Virol on December 16, 2009
Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity (2012) 2.56
Antiretroviral dynamics determines HIV evolution and predicts therapy outcome. Nat Med (2012) 1.61
Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden. J Infect Dis (2011) 1.59
HIV-1 transcription and latency: an update. Retrovirology (2013) 1.49
HIV-1 Populations in Semen Arise through Multiple Mechanisms. PLoS Pathog (2010) 1.47
HIV-1 replication in the central nervous system occurs in two distinct cell types. PLoS Pathog (2011) 1.45
Antiretroviral neurotoxicity. J Neurovirol (2012) 1.43
HIV-1-related central nervous system disease: current issues in pathogenesis, diagnosis, and treatment. Cold Spring Harb Perspect Med (2012) 1.34
Alterations in brain metabolism during the first year of HIV infection. J Neurovirol (2011) 1.20
Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy. J Infect Dis (2011) 1.15
Eradication of HIV from the brain: reasons for pause. AIDS (2011) 1.10
Plasmodium vivax isolates from Cambodia and Thailand show high genetic complexity and distinct patterns of P. vivax multidrug resistance gene 1 (pvmdr1) polymorphisms. Am J Trop Med Hyg (2013) 1.09
Bottlenecks in HIV-1 transmission: insights from the study of founder viruses. Nat Rev Microbiol (2015) 1.08
The gut mucosal viral reservoir in HIV-infected patients is not the major source of rebound plasma viremia following interruption of highly active antiretroviral therapy. J Virol (2011) 1.06
Compartmentalized replication of R5 T cell-tropic HIV-1 in the central nervous system early in the course of infection. PLoS Pathog (2015) 1.04
An example of genetically distinct HIV type 1 variants in cerebrospinal fluid and plasma during suppressive therapy. J Infect Dis (2013) 1.03
Neuropathogenesis of HIV: from initial neuroinvasion to HIV-associated neurocognitive disorder (HAND). Curr HIV/AIDS Rep (2015) 1.03
Viral determinants of HIV-1 macrophage tropism. Viruses (2011) 1.03
HIV-1 pathogenesis: the virus. Cold Spring Harb Perspect Med (2012) 1.03
Central nervous system compartmentalization of HIV-1 subtype C variants early and late in infection in young children. PLoS Pathog (2012) 1.01
Approach to cerebrospinal fluid (CSF) biomarker discovery and evaluation in HIV infection. J Neuroimmune Pharmacol (2013) 0.98
Human immunodeficiency virus (HIV) latency: the major hurdle in HIV eradication. Mol Med (2012) 0.96
Laser capture microdissection assessment of virus compartmentalization in the central nervous systems of macaques infected with neurovirulent simian immunodeficiency virus. J Virol (2013) 0.95
Macrophage-tropic HIV-1 variants from brain demonstrate alterations in the way gp120 engages both CD4 and CCR5. J Leukoc Biol (2012) 0.92
HIV-1 Reservoirs During Suppressive Therapy. Trends Microbiol (2016) 0.92
HIV and neurocognitive dysfunction. Curr HIV/AIDS Rep (2013) 0.91
Compartmentalization, Viral Evolution, and Viral Latency of HIV in the CNS. Curr HIV/AIDS Rep (2015) 0.91
Interplay between Wnt/β-catenin signaling and HIV: virologic and biologic consequences in the CNS. J Neuroimmune Pharmacol (2012) 0.89
Epigenetic regulation of HIV-1 latency in astrocytes. J Virol (2013) 0.89
Different regions of HIV-1 subtype C env are associated with placental localization and in utero mother-to-child transmission. J Virol (2011) 0.89
HIV-1 target cells in the CNS. J Neurovirol (2014) 0.89
The cerebrospinal fluid proteome in HIV infection: change associated with disease severity. Clin Proteomics (2012) 0.88
Clonal amplification and maternal-infant transmission of nevirapine-resistant HIV-1 variants in breast milk following single-dose nevirapine prophylaxis. Retrovirology (2013) 0.87
HIV DNA Is Frequently Present within Pathologic Tissues Evaluated at Autopsy from Combined Antiretroviral Therapy-Treated Patients with Undetectable Viral Loads. J Virol (2016) 0.87
Minocycline fails to modulate cerebrospinal fluid HIV infection or immune activation in chronic untreated HIV-1 infection: results of a pilot study. AIDS Res Ther (2011) 0.86
Bryostatin activates HIV-1 latent expression in human astrocytes through a PKC and NF-ĸB-dependent mechanism. Sci Rep (2015) 0.85
Single genome analysis reveals genetic characteristics of Neuroadaptation across HIV-1 envelope. Retrovirology (2014) 0.84
Profound differences in virus population genetics correspond to protection from CD4 decline resulting from feline lentivirus coinfection. Viruses (2010) 0.84
A Bayesian approach to analyse genetic variation within RNA viral populations. PLoS Comput Biol (2011) 0.84
Eradication of human immunodeficiency virus from brain reservoirs. J Neurovirol (2014) 0.84
Quantifying the role of population subdivision in evolution on rugged fitness landscapes. PLoS Comput Biol (2014) 0.83
CNS reservoirs for HIV: implications for eradication. J Virus Erad (2015) 0.83
A machine learning approach for identifying amino acid signatures in the HIV env gene predictive of dementia. PLoS One (2012) 0.82
HIV eradication symposium: will the brain be left behind? J Neurovirol (2015) 0.82
Cell-cell contact viral transfer contributes to HIV infection and persistence in astrocytes. J Neurovirol (2014) 0.80
Comparative Analysis of Cell-Associated HIV DNA Levels in Cerebrospinal Fluid and Peripheral Blood by Droplet Digital PCR. PLoS One (2015) 0.80
Deep sequencing of hepatitis C virus reveals genetic compartmentalization in cerebrospinal fluid from cognitively impaired patients. Liver Int (2016) 0.78
Emergence of CD4 independence envelopes and astrocyte infection in R5 simian-human immunodeficiency virus model of encephalitis. J Virol (2014) 0.78
Longitudinal Analysis of Cerebrospinal Fluid and Plasma HIV-1 Envelope Sequences Isolated From a Single Donor with HIV Asymptomatic Neurocognitive Impairment. J Virol Antivir Res (2015) 0.78
Neurocognitive decline in HIV patients is associated with ongoing T-cell activation in the cerebrospinal fluid. Ann Clin Transl Neurol (2015) 0.78
Early detection of simian immunodeficiency virus in the central nervous system following oral administration to rhesus macaques. Front Immunol (2013) 0.77
Daily sampling of an HIV-1 patient with slowly progressing disease displays persistence of multiple env subpopulations consistent with neutrality. PLoS One (2011) 0.77
Deep sequencing of HIV-1 variants from paired plasma and cerebrospinal fluid during primary HIV infection. J Virus Erad (2016) 0.76
Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patients. Medicine (Baltimore) (2016) 0.75
A G1-like state allows HIV-1 to bypass SAMHD1 restriction in macrophages. EMBO J (2017) 0.75
Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of Antiretrovirals. AIDS Res Treat (2016) 0.75
Dynamic of CSF and serum biomarkers in HIV-1 subtype C encephalitis with CNS genetic compartmentalization-case study. J Neurovirol (2017) 0.75
Fate of microglia during HIV-1 infection: From activation to senescence? Glia (2016) 0.75
Inferring viral population structures using heteroduplex mobility and DNA sequence analyses. J Virol Methods (2013) 0.75
Envelope gene evolution and HIV-1 neuropathogenesis. J Neuroinfect Dis (2015) 0.75
Analysis of Dominant HIV Quasispecies Suggests Independent Viral Evolution Within Spinal Granulomas Coinfected with Mycobacterium tuberculosis and HIV-1 Subtype C. AIDS Res Hum Retroviruses (2015) 0.75
Early Antiretroviral Therapy is Associated with Lower HIV DNA Molecular Diversity and Lower Inflammation in Cerebrospinal Fluid but Does Not Prevent the Establishment of Compartmentalized HIV DNA Populations. PLoS Pathog (2017) 0.75
A SIV molecular clone that targets the CNS and induces neuroAIDS in rhesus macaques. PLoS Pathog (2017) 0.75
Genetic analyses of HIV env associated with uveitis in antiretroviral-naïve individuals. AIDS (2017) 0.75
CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res (1994) 392.47
A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst Biol (2003) 102.57
Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res (2003) 38.75
Recent developments in the MAFFT multiple sequence alignment program. Brief Bioinform (2008) 22.07
HyPhy: hypothesis testing using phylogenies. Bioinformatics (2004) 17.33
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science (1986) 11.74
Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes. Science (1993) 8.49
Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc Natl Acad Sci U S A (1986) 8.45
PHYML Online--a web server for fast maximum likelihood-based phylogenetic inference. Nucleic Acids Res (2005) 8.20
Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol (2005) 7.91
Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol (2008) 7.54
A cladistic measure of gene flow inferred from the phylogenies of alleles. Genetics (1989) 6.79
The neuropathogenesis of AIDS. Nat Rev Immunol (2005) 6.54
Analysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1. J Virol (1990) 5.20
Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays. J Virol (1994) 4.35
Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network. Ann Intern Med (2001) 3.80
Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol (2008) 3.04
Multiple V1/V2 env variants are frequently present during primary infection with human immunodeficiency virus type 1. J Virol (2004) 2.91
Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity. J Virol (2001) 2.79
Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. J Virol (2002) 2.43
Localization of HIV-1 in human brain using polymerase chain reaction/in situ hybridization and immunocytochemistry. Ann Neurol (1996) 2.22
Demented and nondemented patients with AIDS differ in brain-derived human immunodeficiency virus type 1 envelope sequences. J Virol (1994) 2.21
Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology (2004) 2.18
HIV incidence appears constant in men who have sex with men despite widespread use of effective antiretroviral therapy. AIDS (2004) 2.15
The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia. Proc Natl Acad Sci U S A (2006) 2.13
Diagnosis of primary HIV-1 infection and duration of follow-up after HIV exposure. Karolinska Institute Primary HIV Infection Study Group. AIDS (2000) 2.08
Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDS. J Virol (2003) 2.07
Beta-chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia. Ann Neurol (1998) 2.05
Evolutionary variants of the human immunodeficiency virus type 1 V3 region characterized by using a heteroduplex tracking assay. J Virol (1997) 2.04
Human brain parenchymal microglia express CD14 and CD45 and are productively infected by HIV-1 in HIV-1 encephalitis. Brain Pathol (2002) 2.03
Human immunodeficiency virus type 1 populations in blood and semen. J Virol (1998) 1.99
Diagnosis and management of acute HIV infection. Infect Dis Clin North Am (2007) 1.91
Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment. BMC Infect Dis (2005) 1.91
Mechanisms for the transendothelial migration of HIV-1-infected monocytes into brain. J Immunol (1996) 1.83
Viral dynamics in primary HIV-1 infection. Karolinska Institutet Primary HIV Infection Study Group. AIDS (2000) 1.75
Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication. AIDS (1998) 1.70
Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy. J Virol (2005) 1.68
Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia. PLoS Pathog (2009) 1.66
Macrophage entry mediated by HIV Envs from brain and lymphoid tissues is determined by the capacity to use low CD4 levels and overall efficiency of fusion. Virology (2006) 1.66
Increased human immunodeficiency virus type 1 (HIV-1) env compartmentalization in the presence of HIV-1-associated dementia. J Virol (2005) 1.65
Genetic attributes of cerebrospinal fluid-derived HIV-1 env. Brain (2006) 1.60
Analysis of human immunodeficiency virus type 1 gp160 sequences from a patient with HIV dementia: evidence for monocyte trafficking into brain. J Neurovirol (2000) 1.58
HIV infection of the central nervous system: clinical features and neuropathogenesis. Neurol Clin (2008) 1.50
Neuroinvasion by simian immunodeficiency virus coincides with increased numbers of perivascular macrophages/microglia and intrathecal immune activation. J Neurovirol (1996) 1.50
Tracking changes in HIV-1 envelope quasispecies using DNA heteroduplex analysis. Methods (1997) 1.50
Cerebrospinal fluid interferon-gamma-inducible protein 10 (IP-10, CXCL10) in HIV-1 infection. J Neuroimmunol (2005) 1.49
Turnover of env variable region 1 and 2 genotypes in subjects with late-stage human immunodeficiency virus type 1 infection. J Virol (2003) 1.44
Loss of the N-linked glycosylation site at position 386 in the HIV envelope V4 region enhances macrophage tropism and is associated with dementia. Virology (2007) 1.43
Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course. AIDS (2009) 1.40
Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers. J Neuroimmune Pharmacol (2006) 1.24
Compartmentalized human immunodeficiency virus type 1 present in cerebrospinal fluid is produced by short-lived cells. J Virol (2005) 1.22
Cerebrospinal fluid neopterin in human immunodeficiency virus type 1 infection. Ann Neurol (1990) 1.14
Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy individuals 18-88 years of age. Eur Neurol (1993) 1.13
Efficient amplification of HIV half-genomes from tissue DNA. Nucleic Acids Res (1992) 1.08
HIV-1 populations in blood and breast milk are similar. Virology (2004) 1.06
Interpreting cerebrospinal fluid pleocytosis in HIV in the era of potent antiretroviral therapy. BMC Infect Dis (2007) 1.05
Dynamics of simian immunodeficiency virus populations in blood and cerebrospinal fluid over the full course of infection. J Infect Dis (2007) 1.02
Independent evolution of human immunodeficiency virus type 1 env V1/V2 and V4/V5 hypervariable regions during chronic infection. J Virol (2007) 1.01
The V1-V3 region of a brain-derived HIV-1 envelope glycoprotein determines macrophage tropism, low CD4 dependence, increased fusogenicity and altered sensitivity to entry inhibitors. Retrovirology (2008) 1.00
Cerebrospinal fluid mononuclear cell counts influence CSF HIV-1 RNA levels. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.00
Sequential turnover of human immunodeficiency virus type 1 env throughout the course of infection. J Virol (2006) 0.98
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol (2008) 7.54
Architecture and secondary structure of an entire HIV-1 RNA genome. Nature (2009) 6.12
Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID. Proc Natl Acad Sci U S A (2011) 4.68
HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis (2010) 3.46
Multiple V1/V2 env variants are frequently present during primary infection with human immunodeficiency virus type 1. J Virol (2004) 2.91
Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis (2006) 2.74
Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog (2013) 2.44
Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis (2012) 2.37
Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure. J Infect Dis (2006) 2.36
Accuracy of the TRUGENE HIV-1 genotyping kit. J Clin Microbiol (2003) 2.32
Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop. J Virol (2002) 2.19
Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. J Clin Invest (2012) 2.05
Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates. AIDS (2007) 2.03
Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res Ther (2010) 1.99
HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2002) 1.94
Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy. J Infect Dis (2007) 1.92
Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment. BMC Infect Dis (2005) 1.91
Progressive multifocal leukoencephalopathy in HIV-1 infection. Lancet Infect Dis (2009) 1.82
Development of diagnostic criteria for serious non-AIDS events in HIV clinical trials. HIV Clin Trials (2010) 1.75
Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease. J Virol (2002) 1.71
Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. AIDS Res Hum Retroviruses (2003) 1.68
Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia. PLoS Pathog (2009) 1.66
Covariation of amino acid positions in HIV-1 protease. Virology (2003) 1.65
Increased human immunodeficiency virus type 1 (HIV-1) env compartmentalization in the presence of HIV-1-associated dementia. J Virol (2005) 1.65
Determination of the underlying cause of death in three multicenter international HIV clinical trials. HIV Clin Trials (2008) 1.65
Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden. J Infect Dis (2011) 1.59
Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog (2011) 1.57
Antiretroviral therapy and central nervous system HIV type 1 infection. J Infect Dis (2008) 1.56
The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence? BMC Infect Dis (2011) 1.54
Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy. AIDS (2004) 1.51
Cerebrospinal fluid interferon-gamma-inducible protein 10 (IP-10, CXCL10) in HIV-1 infection. J Neuroimmunol (2005) 1.49
Processing sites in the human immunodeficiency virus type 1 (HIV-1) Gag-Pro-Pol precursor are cleaved by the viral protease at different rates. Retrovirology (2005) 1.48
HIV-1 Populations in Semen Arise through Multiple Mechanisms. PLoS Pathog (2010) 1.47
Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy. J Acquir Immune Defic Syndr (2008) 1.47
Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection. J Acquir Immune Defic Syndr (2008) 1.46
HIV-1 replication in the central nervous system occurs in two distinct cell types. PLoS Pathog (2011) 1.45
Turnover of env variable region 1 and 2 genotypes in subjects with late-stage human immunodeficiency virus type 1 infection. J Virol (2003) 1.44
Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. J Infect Dis (2013) 1.42
Alphavirus replicon particles as candidate HIV vaccines. IUBMB Life (2002) 1.41
Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course. AIDS (2009) 1.40
Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complex. J Infect Dis (2007) 1.36
Measuring allelic heterogeneity in Plasmodium falciparum by a heteroduplex tracking assay. Am J Trop Med Hyg (2005) 1.35
Role of low CD4 levels in the influence of human immunodeficiency virus type 1 envelope V1 and V2 regions on entry and spread in macrophages. J Virol (2005) 1.34
Undetectable cerebrospinal fluid HIV RNA and beta-2 microglobulin do not indicate inactive AIDS dementia complex in highly active antiretroviral therapy-treated patients. J Acquir Immune Defic Syndr (2005) 1.32
Correlation between env V1/V2 region diversification and neutralizing antibodies during primary infection by simian immunodeficiency virus sm in rhesus macaques. J Virol (2004) 1.32
Cross-sectional detection of acute HIV infection: timing of transmission, inflammation and antiretroviral therapy. PLoS One (2011) 1.32
Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. BMC Neurol (2009) 1.32
A strongly transdominant mutation in the human immunodeficiency virus type 1 gag gene defines an Achilles heel in the virus life cycle. J Virol (2009) 1.30
Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment. Antivir Ther (2005) 1.28
Change in brain magnetic resonance spectroscopy after treatment during acute HIV infection. PLoS One (2012) 1.25
Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers. J Neuroimmune Pharmacol (2006) 1.24
The choreography of HIV-1 proteolytic processing and virion assembly. J Biol Chem (2012) 1.23
CSF neurofilament protein (NFL) -- a marker of active HIV-related neurodegeneration. J Neurol (2007) 1.22
Compartmentalized human immunodeficiency virus type 1 present in cerebrospinal fluid is produced by short-lived cells. J Virol (2005) 1.22
Is it time to rethink how neuropsychological tests are used to diagnose mild forms of HIV-associated neurocognitive disorders? Impact of false-positive rates on prevalence and power. Neuroepidemiology (2013) 1.17
Limitations to contact tracing and phylogenetic analysis in establishing HIV type 1 transmission networks in Cuba. AIDS Res Hum Retroviruses (2007) 1.16
Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection. AIDS Res Hum Retroviruses (2008) 1.15
A substantial transmission bottleneck among newly and recently HIV-1-infected injection drug users in St Petersburg, Russia. J Infect Dis (2010) 1.15
Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy. J Infect Dis (2011) 1.15
Viral protease inhibitors. Handb Exp Pharmacol (2009) 1.14
Vaccination of macaques with SIV immunogens delivered by Venezuelan equine encephalitis virus replicon particle vectors followed by a mucosal challenge with SIVsmE660. Vaccine (2005) 1.14
Subtype-specific conformational differences within the V3 region of subtype B and subtype C human immunodeficiency virus type 1 Env proteins. J Virol (2007) 1.14
Increased adhesion molecule and chemokine receptor expression on CD8+ T cells trafficking to cerebrospinal fluid in HIV-1 infection. J Infect Dis (2004) 1.14
Genetic characteristics of the V3 region associated with CXCR4 usage in HIV-1 subtype C isolates. Virology (2006) 1.12
HIV pathogenesis: dynamics and genetics of viral populations and infected cells. Cold Spring Harb Perspect Med (2013) 1.11
The genetic bottleneck in vertical transmission of subtype C HIV-1 is not driven by selection of especially neutralization-resistant virus from the maternal viral population. J Virol (2011) 1.10
Role of invariant Thr80 in human immunodeficiency virus type 1 protease structure, function, and viral infectivity. J Virol (2006) 1.10
Timed Gait test: normative data for the assessment of the AIDS dementia complex. J Clin Exp Neuropsychol (2006) 1.09
Comparison of SIV and HIV-1 genomic RNA structures reveals impact of sequence evolution on conserved and non-conserved structural motifs. PLoS Pathog (2013) 1.08
Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS One (2009) 1.08
HIV-1 populations in blood and breast milk are similar. Virology (2004) 1.06
Evolution of the HIV-1 env gene in the Rag2-/- gammaC-/- humanized mouse model. J Virol (2009) 1.05
Cerebrospinal fluid-based kinetic biomarkers of axonal transport in monitoring neurodegeneration. J Clin Invest (2012) 1.05
HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia. J Infect Dis (2005) 1.04
HIV-1 transmission during early antiretroviral therapy: evaluation of two HIV-1 transmission events in the HPTN 052 prevention study. PLoS One (2013) 1.04
Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals. AIDS Res Hum Retroviruses (2009) 1.04
Quantification of entry phenotypes of macrophage-tropic HIV-1 across a wide range of CD4 densities. J Virol (2013) 1.04
An example of genetically distinct HIV type 1 variants in cerebrospinal fluid and plasma during suppressive therapy. J Infect Dis (2013) 1.03